CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
Status:
Not yet recruiting
Trial end date:
2030-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase II trial testing disease-specific myeloablative conditioning regimens for
preparatory cytoreduction of patients receiving allogeneic HLA-compatible related or
unrelated transplants of GCSF-mobilized peripheral blood stem cells (PBSC) depleted of
T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system. The
CliniMACS Fractionation system is a method that positively selects CD34+ progenitor cells
from PBSC by immunoadsorption of cells binding on anti CD34 monoclonal antibody to
paramagnetic beads, which can then be isolated by passage through a magnetized column and
released by agitation of beads. Two conditioning regimens have been used successfully with an
alternative similar system, isolex, which is no longer being manufactured.